OTCMKTS:OPHLY Ono Pharmaceutical (OPHLY) Stock Price, News & Analysis $4.94 -0.05 (-1.08%) As of 05/29/2026 03:50 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartHeadlinesSEC FilingsShort InterestBuy This Stock About Ono Pharmaceutical Stock (OTCMKTS:OPHLY) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Ono Pharmaceutical alerts:Sign Up Key Stats Today's Range$4.93▼$5.0750-Day Range$4.70▼$5.4252-Week Range$3.35▼$5.75Volume28,498 shsAverage Volume26,316 shsMarket CapitalizationN/AP/E Ratio1.08Dividend Yield335.50%Price TargetN/AConsensus RatingN/A Company Overview Ono Pharmaceutical Co., Ltd. is a Japan-based pharmaceutical company engaged in the research, development, manufacturing and marketing of prescription drugs and diagnostics. Headquartered in Osaka, the company traces its origins to the early 18th century and has grown into a global specialty‐pharmaceutical firm. Its product portfolio spans oncology, immunology, allergy and inflammatory diseases, with a notable focus on novel immunotherapies. In oncology, Ono Pharmaceutical is best known for co‐developing and commercializing nivolumab (Opdivo), an anti–PD‐1 immune checkpoint inhibitor developed in partnership with Bristol‐Myers Squibb. Beyond cancer immunotherapy, the company researches small‐molecule drugs and antibody therapeutics targeting various immunological pathways. It also produces in vitro diagnostics and laboratory reagents that support disease detection and treatment monitoring. Ono Pharmaceutical operates primarily in Japan but has extended its reach globally through strategic alliances and licensing agreements. In overseas markets, the company collaborates with multinational partners to secure regulatory approvals and to manage manufacturing and distribution. Ono’s ongoing pipeline includes compounds in clinical trials for solid tumors, hematological malignancies and immune‐mediated disorders.AI Generated. May Contain Errors. Read More Receive OPHLY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ono Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. OPHLY Stock News HeadlinesOno Pharmaceutical Co. - depositary receipt (OPHLY) price target decreased by 13.89% to 2.21February 24, 2026 | msn.comPfizer says cancer therapy Braftovi improved survival in late-stage trialFebruary 17, 2026 | msn.comSpaceX will mint billionaires. You won't be one of them.By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billion - you'd be buying at $1.75 trillion. But one small, publicly traded company sits directly in SpaceX's path, still priced like Wall Street hasn't noticed. It powers the infrastructure Musk's operation can't run without. Dylan Jovine is naming the ticker free - before the June S-1 closes the window.May 30 at 1:00 AM | Behind the Markets (Ad)Ono Pharmaceutical Co. - Depositary receipt (OPHLY) price target increased by 28.77% to 2.56February 4, 2026 | msn.comOno Shares Replay Information for 44th Annual J.P. Morgan Healthcare Conference PresentationJanuary 15, 2026 | finance.yahoo.comOno Pharmaceutical Co., - depositary receipt (OPHLY) price target increased by 30.66% to 1.99December 22, 2025 | msn.comOno Pharmaceutical Co., - Depositary Receipt (OPHLY) Price Target Decreased by 17.63% to 1.52November 17, 2025 | msn.comPRISM BioLab Achieved Initial Milestone and Receives the Milestone Payment in Drug Discovery Collaboration with Ono Pharmaceutical Co., Ltd.November 14, 2025 | finance.yahoo.comSee More Headlines OPHLY Stock Analysis - Frequently Asked Questions How have OPHLY shares performed this year? Ono Pharmaceutical's stock was trading at $4.55 on January 1st, 2026. Since then, OPHLY stock has increased by 8.5% and is now trading at $4.9350. How do I buy shares of Ono Pharmaceutical? Shares of OPHLY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Today5/30/2026Next Earnings (Estimated)8/03/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Drug Manufacturers - General Sub-IndustryN/A Current SymbolOTCMKTS:OPHLY CIK940821 Webwww.ono.co.jp Phone(166) 263-5670FaxN/AEmployees3,761Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E Ratio1.08 Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report This page (OTCMKTS:OPHLY) was last updated on 5/30/2026 by MarketBeat.com Staff. From Our PartnersTrump just signed itA recent policy development is drawing attention from income-focused investors. According to one analyst, c...Investors Alley | SponsoredYour book attachedYour Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...Profits Run | SponsoredOne hidden supplier shipped 5 billion parts to SpaceXMost investors are focused on the historic $1.75 trillion SpaceX IPO expected around June 30. But there's a le...Weiss Ratings | SponsoredHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | SponsoredOne page of the SpaceX S-1 will move this stock overnightWhen SpaceX files its S-1 in June, the SEC will require full disclosure of operating expenses - including powe...Behind the Markets | SponsoredCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredMusk lights fire under Swiss chipmaker?While investors chase the SpaceX IPO, one little-known Swiss chipmaker - 148 times smaller than NVIDIA - has q...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ono Pharmaceutical Co., Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ono Pharmaceutical With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free OPHLY Stock Alerts